Navigation Links
AMP concerned about the structure and application of gap fill payment amounts
Date:7/11/2013

Bethesda, MD, July 11, 2013: The Association for Molecular Pathology (AMP) submitted comments to the Centers for Medicare and Medicaid Services (CMS) expressing serious concerns about the gap fill process. "Overall, the process neglects to take into account the unique and valuable expertise of the professionals who interpret the data," said AMP President, Jennifer L. Hunt, MD, MEd, "Acknowledgement of the time, resources, and risk assumed by the specially trained individuals who analyze the complex datasets is absent from the current structure. It is those physicians and doctoral scientists who are legally responsible for the accuracy of the results."

AMP's comments point out that since the new codes took effect on January 1, 2013, many laboratories have gone without reimbursement for their services. This lack of coverage is a result of payment amounts that have not yet been determined as well as those in which the cost exceeds the reimbursement amount. "The current payment standard is unsustainable," said Jan A. Nowak, MD, PhD, Co-Chair of the AMP Economic Affairs Committee (EAC). "Labs are being forced to either discontinue critical tests or endure significant revenue shortages due to lack of coverage under the existing policies." With laboratories unable to perform certain tests, it is ultimately the patient who suffers.

The absence of transparency within the gap fill process is another significant issue raised by AMP in their comments. Alternative solutions exist that are supported by AMP and other professional societies. These solutions offer the transparency, data collection procedures, payment structures, and the flexibility to adapt as needed based on public input. One solution would have been placement of the new molecular pathology CPT codes on the Physician Fee Schedule (PFS). "Significant effort was spent in determining the practice expense and professional work involved for most of the codes," said Aaron D. Bossler, MD, PhD, C
'/>"/>

Contact: Catherine Davidge
cdavidge@amp.org
301-634-7400
Association for Molecular Pathology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Ohioans love their lakes, but are concerned for their future
2. MacaInfo.org Offers In-Depth Answers the 20 Most Common Questions People Have about Maca
3. Scientists discover new details about rice blast, a deadly plant fungus
4. Study of oceans past raises worries about their future
5. Questions rise about seeding for ocean C02 sequestration
6. Nothing fishy about it: Fish oil can boost the immune system
7. Ultrafine particles raise concerns about improved cookstoves
8. Genes may be reason some kids are picky about food
9. After the Genome tackles tough questions about medicine, miracles and morality
10. New checklist brings information about Cucurbitaceae up to date
11. True grit erodes assumptions about evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Office has granted an exclusive license of a novel ... Inc., which plans to initiate early-stage human clinical trials ... Gary Landreth, PhD, the Riuko and Archie G. Co ... PhD, co-founded ReXceptor after discovering that bexarotene (a medication ...
... and Oxford, UK Cancer cells are a problem for ... blithely metastasize to set up shop in places where they ... this way is a tumor suppressor named p53. This protein ... those that are damaged beyond repair. Not surprisingly, p53,s critical ...
... across the UK has shown a grass hybrid species ... The BBSRC-funded scientists, from Rothamsted Research, the James Hutton ... at Aberystwyth University, Lancaster University and the University of ... perennial ryegrass ( Lolium perenne ) with a closely ...
Cached Biology News:Research spinoff ReXceptor gets license for Alzheimer's treatment 2Reviving a foe of cancer 2New grass hybrid could help reduce the likelihood of flooding 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/28/2015)... ... ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to ... such as the Fonz in a lab coat and Large Marge have been posted on ... , FireflySci is proud to be the only cuvette manufacturer is the world ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in helping ... one of the top 5000 companies listed on the 2015 Inc. 5000 , ... is truly an honor to be recognized as one of America’s fastest growing companies. ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... , , , , ... Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its first fiscal ... from the $1,394,000 reported for the same period last year. , ... compared to a net profit for the same period of the prior fiscal year ...
... , , , LEXINGTON, ... for Genome Resources (NCGR) has selected febit,s DNA-capture method, HybSelect(TM), ... of the most devastating childhood diseases with the ultimate goal ... genetic diseases in prospective parents. , , ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3